The value of positron emission tomography (PET) in the management of patients with thyroid cancer

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 22, Issue 6, 2008, Pages 1047-1059

  Robbins, Richard J ^b   Larson, Steven M ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b NONE

Author keywords

Fluoro deoxyglucose; PET scanning; Thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 124; IODINE 131; RADIOACTIVE IODINE; THYROGLOBULIN; THYROTROPIN;

CANCER PATIENT; CANCER SURVIVAL; CERVICAL LYMPH NODE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISTANT METASTASIS; DRUG MEGADOSE; ECHOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MEDICAL ASSESSMENT; METASTASIS; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; REVIEW; SENSITIVITY AND SPECIFICITY; THYROID CANCER; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

CARCINOMA, PAPILLARY, FOLLICULAR; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THYROID NEOPLASMS;

EID: 56849091096     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.10.001     Document Type: Review

References (53)

1. Warburg O., Wind F., and Neglers E. On the metabolism of tumors in the body. In: Warburg O. (Ed). Metabolism of tumors (1930), Constable, London 254-270
2. Hatanaka M. Transport of sugars in tumor cell membranes. Biochimica et Biophysica Acta 355 1 (1974) 77-104
3. Weber G. Enzymology of cancer cells (second of two parts). The New England Journal of Medicine 296 10 (1977) 541-551
4. Sokoloff L., Reivich M., Kennedy C., et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. Journal of Neurochemistry 28 5 (1977) 897-916
5. Reivich M., Alavi A., Wolf A., et al. Glucose metabolic rate kinetic model parameter determination in humans: the lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose. Journal of Cerebral Blood Flow and Metabolism 5 2 (1985) 179-192
6. Joensuu H., and Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. Journal of Nuclear Medicine 28 5 (1987) 910-914
7. Feine U., Lietzenmayer R., Hanke J.P., et al. 18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I. Nuklearmedizin 34 4 (1995) 127-134
8. Feine U., Lietzenmayer R., Hanke J.P., et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. Journal of Nuclear Medicine 37 9 (1996) 1468-1472
9. Grunwald F., Schomburg A., Bender H., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. European Journal of Nuclear Medicine 23 3 (1996) 312-319
10. Scott G.C., Meier D.A., and Dickinson C.Z. Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide. Journal of Nuclear Medicine 36 10 (1995) 1843-1845
11. Grunwald F., Menzel C., Bender H., et al. Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 7 3 (1997) 327-335
12. Dietlein M., Scheidhauer K., Voth E., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. European Journal of Nuclear Medicine 24 11 (1997) 1342-1348
13. Altenvoerde G., Lerch H., Kuwert T., et al. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbeck's Archives of Surgery 383 2 (1998) 160-163
14. Huang T.S., Chieng P.U., Chang C.C., et al. Positron emission tomography for detecting iodine-131 nonvisualized metastasis of well-differentiated thyroid carcinoma: two case reports. Journal of Endocrinological Investigation 21 6 (1998) 392-398
15. Jadvar H., McDougall I.R., and Segall G.M. Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography. Nuclear Medicine Communications 19 6 (1998) 547-554
16. Chung J.K., So Y., Lee J.S., et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. Journal of Nuclear Medicine 40 6 (1999) 986-992
17. Alnafisi N.S., Driedger A.A., Coates G., et al. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. Journal of Nuclear Medicine 41 6 (2000) 1010-1015
18. Wang W., Macapinlac H., Larson S.M., et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. The Journal of Clinical Endocrinology and Metabolism 84 7 (1999) 2291-2302
19. Lind P., Kresnik E., Kumnig G., et al. 18F-FDG-PET in the follow-up of thyroid cancer. Acta Medica Austriaca 30 1 (2003) 17-21
20. Larson S.M., and Robbins R. Positron emission tomography in thyroid cancer management. Seminars in Roentgenology 37 2 (2002) 169-174
21. Hooft L., Hoekstra O.S., Deville W., et al. Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. The Journal of Clinical Endocrinology and Metabolism 86 8 (2001) 3779-3786
22. Davison J.M., Stocker D.J., Montilla-Soler J.L., et al. The added benefit of a dedicated neck F-18 FDG PET-CT imaging protocol in patients with suspected recurrent differentiated thyroid carcinoma. Clinical Nuclear Medicine 33 7 (2008) 464-468
23. Stojadinovic A., Hoos A., Ghossein R.A., et al. Hurthle cell carcinoma: a 60-year experience. Annals of Surgical Oncology 9 2 (2002) 197-203
24. Plotkin M., Hautzel H., Krause B.J., et al. Implication of 2-18fluor-2-deoxyglucose positron emission tomography in the follow-up of Hurthle cell thyroid cancer. Thyroid 12 2 (2002) 155-161
25. Lowe V.J., Mullan B.P., Hay I.D., et al. 18F-FDG PET of patients with Hurthle cell carcinoma. Journal of Nuclear Medicine 44 9 (2003) 1402-1406
26. Pryma D.A., Schoder H., Gonen M., et al. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients. Journal of Nuclear Medicine 47 8 (2006) 1260-1266
27. Adler L.P., and Bloom A.D. Positron emission tomography of thyroid masses. Thyroid 3 3 (1993) 195-200
28. Bloom A.D., Adler L.P., and Shuck J.M. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 114 4 (1993) 728-734 [discussion: 734-725]
29. Uematsu H., Sadato N., Ohtsubo T., et al. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors. Journal of Nuclear Medicine 39 3 (1998) 453-459
30. Smith R.B., Robinson R.A., Hoffman H.T., et al. Preoperative FDG-PET imaging to assess the malignant potential of follicular neoplasms of the thyroid. Otolaryngology Head and Neck Surgery 138 1 (2008) 101-106
31. Cohen M.S., Arslan N., Dehdashti F., et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 130 6 (2001) 941-946
32. Van den Bruel A., Maes A., De Potter T., et al. Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. The Journal of Clinical Endocrinology and Metabolism 87 4 (2002) 1517-1520
33. Davis P.W., Perrier N.D., Adler L., et al. Incidental thyroid carcinoma identified by positron emission tomography scanning obtained for metastatic evaluation. American Surgeon 67 6 (2001) 582-584
34. Katz S.C., and Shaha A. PET-associated incidental neoplasms of the thyroid. Journal of the American College of Surgeons 207 2 (2008) 259-264
35. Zoller M., Kohlfuerst S., Igerc I., et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?. European Journal of Nuclear Medicine and Molecular Imaging 34 4 (2007) 487-495
36. Freudenberg L.S., Frilling A., Kuhl H., et al. Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. European Radiology 17 12 (2007) 3139-3147
37. Leboulleux S., Schroeder P.R., Schlumberger M., et al. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nature Clinical Practice Endocrinology & Metabolism 3 2 (2007) 112-121
38. Seiboth L., Van Nostrand D., Wartofsky L., et al. Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer. Thyroid 18 2 (2008) 103-111
39. Sisson J.C., Ackermann R.J., Meyer M.A., et al. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. The Journal of Clinical Endocrinology and Metabolism 77 4 (1993) 1090-1094
40. Hosaka Y., Tawata M., Kurihara A., et al. The regulation of two distinct glucose transporter (GLUT1 and GLUT4) gene expressions in cultured rat thyroid cells by thyrotropin. Endocrinology 131 1 (1992) 159-165
41. van Tol K.M., Jager P.L., Piers D.A., et al. Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 12 5 (2002) 381-387
42. Moog F., Linke R., Manthey N., et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. Journal of Nuclear Medicine 41 12 (2000) 1989-1995
43. Petrich T., Borner A.R., Otto D., et al. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 29 5 (2002) 641-647
44. Iagaru A., Kalinyak J.E., and McDougall I.R. F-18 FDG PET/CT in the management of thyroid cancer. Clinical Nuclear Medicine 32 9 (2007) 690-695
45. Hoie J., Stenwig A., Kullmann G., et al. Distant metastases in papillary thyroid cancer. A review of 91 patients. Cancer 61 (1988) 1-6
46. Schlumberger M. Papillary and follicular thyroid carcinoma. The New England Journal of Medicine 338 (1998) 297-306
47. Rivera M., Ghossein R.A., Schoder H., et al. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 113 1 (2008) 48-56
48. Wang W., Larson S.M., Fazzari M., et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. The Journal of Clinical Endocrinology and Metabolism 85 3 (2000) 1107-1113
49. Robbins R.J., Wan Q., Grewal R.K., et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. The Journal of Clinical Endocrinology and Metabolism 91 2 (2006) 498-505
50. Wang W., Larson S.M., Tuttle R.M., et al. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 11 12 (2001) 1169-1175
51. Sgouros G., Kolbert K.S., Sheikh A., et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. Journal of Nuclear Medicine 45 8 (2004) 1366-1372
52. Jentzen W., Freudenberg L., Eising E.G., et al. Optimized 124I PET dosimetry protocol for radio-iodine therapy of differentiated thyroid cancer. Journal of Nuclear Medicine 49 6 (2008) 1017-1023
53. Phan H.T., Jager P.L., Paans A.M., et al. The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 35 5 (2008) 958-965